For the latest updates on how we are managing changes due to COVID-19 please click here.

The Ora-CAC® Model: Evaluating the Efficacy of Anti-Allergic and Anti-Inflammatory Products

Identifying the onset and duration of anti-allergic and anti-inflammatory products can be vital to your development success. For over 30 years, the Ora Conjunctival Allergen Challenge Model (Ora-CAC®) has been used to evaluate every anti-allergic agent for the treatment of allergic conjunctivitis. In this webinar presented on December 10, 2019, Paul Gomes (Vice President, Allergy) shares various applications of this model such as Phase 2 dose ranging, Phase 3 pivotals, and clinical bioequivalence. He also discusses utilization of the Ora-CAC® Model as a high through-put screen of anti-inflammatory agents.

Click here to view